drugset / Trial / NCT03858725

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

NCT03858725

Phase 1 Completed 36 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, fasted, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-374 5 mg in healthy volunteers.

Timeline

Start
2019-02-26
Primary completion
2019-04-05
Completion
2019-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject D569 Unknown Oral
Subject Tofacitinib Small molecule 5 mg Oral

Indications